Several clinical, molecular, and pathological prognostic factors for patients with IDH-mutant astrocytoma have been identified, including age, tumor size, primary tumor site, surgical outcome, mitotic index, and CDKN2A/B homozygous deletion [14–16]. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).